Usage of laser ablation in complex treatment of metastatic liver lesions

In this research we analyzed treatment results of 28 patients with metastatic liver lesions who underwent laser ablation for the period from March, 2017 to March, 2019. Recently the removal of primary sites for R0 and D1, D2 lymphodissection was performed and also received chemotherapy. Laser ablation of metastatic liver lesions (The size of formations was from 10 - 40 mm, average size 29,8 1,7 mm) was performed percutaneously under ultrasound scanning in real time mode. We used the unit of company ECHO LASER for laser ablation, manufactured in Italy. Ultrasound, MRI andCT with intravenous contrast were used for the dynamically control of ablation effectiveness. In early postoperative period were noticed 3-days pain syndrome (could be regulated by the painkillers) and 10-days changing of biochemical analyses (ALT, AST, Alk phos). Either subcapsular hematoma in the area of light guide facility (didn’t required for surgery intervention) was registered. During the morphological study of ablation area (6 months after destruction) was noticed 4 stage pathomorphosis (Lushnikov). Average bed day stood at 4 days. 1-year life expectancy stood at 98%, 2-years stood at 79%.Usage of laser ablation allows to perform surgical intervention with insufficient volume of liver and somatically burdened patients that cannot be performed liver resection.